Background About 10 000 persons are diagnosed as having carcinoma of the oral cavity or
the throat in Germany every year. Squamous-cell carcinoma accounts for 95% of cases …

Opinion statement Head and neck squamous cell carcinoma is now the 8th most common
cancer affecting men in the United States largely due to a rising epidemic of oropharynx …

Chemotherapy has been reported to induce epithelial-mesenchymal transition (EMT) in
tumor cells, which is a critical step in the process of metastasis leading to cancer spreading …

Background The efficacy and safety of a novel combination of weekly paclitaxel and the
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …

Purpose: This study sought to determine the efficacy and safety profile of lapatinib in patients
with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) …

PURPOSE: Normal tissues tolerance limits the use of reirradiation for recurrent head-and-
neck cancers (HNC). Stereotactic body radiotherapy (SBRT) could offer precise irradiation …

Head and neck squamous cell carcinoma (HNSCC) of multi-factorial etiopathogenesis is
rising worldwide. Treatment-associated toxicity problems and treatment failure in advanced …

Despite recent advances in radiotherapy and chemotherapy, survival rates for squamous
cell carcinoma of the head and neck (SCCHN) have remained poor. The focus of SCCHN …

Distant metastases from head and neck squamous cell carcinoma (HNSCC), though rare at
initial presentation, remain an important manifestation of cancer recurrence and mortality …

The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases
the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma …